Skip to main content

Renal Autotransplantation

Renal autotransplantation (RAT) is a complex surgical procedure in which a patient's own kidney is removed (nephrectomy), repaired or reconstructed on a back table (ex vivo bench surgery), and then reimplanted into the ipsilateral iliac fossa — analogous to a kidney transplant but using the patient's own organ, thereby eliminating the need for immunosuppression.[1][2] It is a rarely performed but widely accepted nephron-sparing technique reserved for highly select patients with complex renovascular, ureteral, oncologic, or pain-syndrome conditions where conventional approaches have failed or are unsuitable.[3]

Within the upper-tract reconstructive ladder, RAT sits at the salvage tier — beyond Boari flap and psoas hitch, beyond ileal ureter, and reserved for the patient in whom every other reconstructive option has been exhausted or is precluded by anatomy, prior surgery, or disease biology.

Historical Context​

First described by Hardy in 1963, RAT was popularized in the 1970s–1980s primarily for complex renovascular disease. In a landmark Cleveland Clinic series (1972–1988), 108 patients underwent RAT for renal artery disease (62%), ureteral replacement (25%), and renal cell carcinoma in a solitary kidney (13%), with success rates of 85–96% across indications.[2] A nationwide analysis of 817 cases from 2002–2012 confirmed that procedural volume has been increasing, with 97.7% performed at urban teaching hospitals.[4]

Indications​

RAT remains an important management strategy for the following conditions.[1][5][6]

1. Complex Renovascular Disease​

  • The most common historical indication, particularly for complex branch renal artery aneurysms not amenable to in situ repair.[2][7]
  • Ex vivo repair allows unlimited cold ischemia time for meticulous microvascular reconstruction of branch vessels, compared with the 30–45-minute warm ischemia limit of in situ repair.[7]
  • In a series of 24 patients with complex renal artery aneurysms treated by ex vivo surgery and autotransplantation, kidney patency was 93% at a mean follow-up of 47 months, with hypertension cured or improved in 59%.[7]
  • Also used for fibromuscular dysplasia, renal artery dissection, and renovascular hypertension refractory to endovascular approaches.[1][2]

2. Ureteral Stricture Disease and Ureteral Trauma​

  • The most common modern indication, accounting for up to 79% of cases in some series.[6]
  • Indicated when the entire ureter or a major portion requires replacement and conventional reconstructive options (ureteroureterostomy, Boari flap, psoas hitch, ileal interposition) have failed or are not feasible.[1][2]
  • Success rate of 92% in the Cleveland Clinic series, with well-preserved renal function and minimal chronic bacteriuria.[2]
  • Particularly valuable after iatrogenic ureteral injury, radiation-induced strictures, and retroperitoneal fibrosis.[1][8]
  • See also Ureteral Stricture for the broader management algorithm.

3. Loin Pain–Hematuria Syndrome (LPHS)​

  • RAT serves as a form of nephron-sparing renal denervation for patients with debilitating, narcotic-dependent flank pain and hematuria with negative comprehensive urological evaluation.[9][10]
  • Pain resolution occurs in approximately 65–76% of patients, with durable relief beyond 10 years in some cases.[5][10][11]
  • However, 35% experience pain recurrence, typically within 2 years, and some require transplant nephrectomy.[5][10]
  • Renal neurectomy alone has an inferior recurrence rate (67%) compared with autotransplantation.[11]
  • Careful patient selection with multidisciplinary evaluation (including psychiatric assessment) is essential, as no predictors of pain recurrence have been identified.[1][5]

4. Renal Cell Carcinoma (RCC)​

  • Indicated for complex tumors in a solitary kidney or bilateral synchronous tumors where in situ partial nephrectomy is not feasible, to avoid dialysis dependence.[1][12][13]
  • Ex vivo partial nephrectomy and autotransplantation were successful in 85% of patients in the Cleveland Clinic series.[2]
  • However, local recurrence rates of 11–25% have been reported, necessitating CT surveillance every 3–6 months postoperatively.[14][15]
  • In situ partial nephrectomy is preferred when technically feasible due to lower morbidity.[2]

5. Upper Tract Urothelial Carcinoma (UTUC)​

  • Used in patients with tumors in a solitary kidney or bilateral disease where nephroureterectomy would render the patient anephric.[16][17][18]
  • Pyelovesicostomy after autotransplantation allows simplified endoscopic surveillance and intravesical chemotherapy instillation.[18]
  • Long-term follow-up (up to 20 years) shows that recurrence in the autotransplanted kidney is possible, particularly with low-grade tumors that may progress to invasive disease.[19]
  • Not recommended in patients with a normal contralateral kidney, where standard nephroureterectomy is preferred.[19]

6. Nutcracker Syndrome​

  • RAT has been used as salvage therapy for recurrent nutcracker syndrome after failed renal vein transposition, with successful resolution of symptoms.[20]

7. Refractory Nephrolithiasis​

  • Rare indication; with advances in endourology and minimally invasive stone management, this application has become exceedingly uncommon.[1]

Surgical Technique​

The procedure consists of three phases.[1][7][12][13]

Phase 1 — Nephrectomy​

  • The kidney is mobilized and removed, preserving maximal length of the renal artery, renal vein, and ureter.
  • Historically performed via open flank or transabdominal incision; increasingly performed laparoscopically (applying principles of laparoscopic living donor nephrectomy), which reduces donor-site morbidity.[6][13]

Phase 2 — Ex Vivo Bench Surgery​

  • The kidney is immediately flushed with cold preservation solution (e.g., University of Wisconsin solution or histidine-tryptophan-ketoglutarate) and placed on ice.
  • Warm ischemia time is minimized (typically 1–10 minutes); cold ischemia time ranges from 86–209 minutes depending on the complexity of the reconstruction.[12][21]
  • On the back table, the specific pathology is addressed:
    • Vascular reconstruction (aneurysmorrhaphy, bypass grafting, branch vessel repair)[7]
    • Tumor excision and renorrhaphy[12][13]
    • Ureteral trimming and preparation for reimplantation[6]

Phase 3 — Autotransplantation​

  • The kidney is implanted into the ipsilateral iliac fossa through a Gibson incision (similar to standard renal transplant technique).
  • The renal artery is anastomosed to the external or internal iliac artery (end-to-side), and the renal vein to the external iliac vein.[7][13]
  • Urinary continuity is re-established via ureteroneocystostomy (direct ureteral reimplantation into the bladder) or pyelovesicostomy (direct pelvis-to-bladder anastomosis) when the ureter is absent or unusable.[16][18]
  • A ureteral stent is typically placed.

Minimally Invasive and Robotic Approaches​

Robot-assisted laparoscopic renal autotransplantation (RAKAT) has emerged as a feasible alternative with potentially improved perioperative outcomes.[1][21][22]

  • Single-port robotic autotransplantation using the da Vinci SP platform allows the entire procedure (nephrectomy and reimplantation) through a single 5 cm periumbilical incision without patient repositioning.[21][22] See Single-Port Robotics for the broader incision atlas.
  • In a series of 8 single-port cases, operative times ranged from 366–701 minutes, median hospital stay was 3 days (vs 6 days for open), and all grafts maintained function with no complications at median 13-month follow-up.[21]
  • Robotic vascular anastomosis times range from 52–92 minutes.[22]
  • Comparative studies between robotic and open approaches are lacking, but early data suggest comparable graft success with reduced length of stay.[1][3]

Outcomes​

Outcome MeasureDataReferences
Long-term graft function90–97% at >6-year median follow-up[1][2]
Graft failure rate9.7–10.7%[1][3]
Mortality0–1.3%[3][4]
Overall morbidity (nationwide, all grades)46.2%[4]
High-grade complications (Clavien ≥ IIIa)14.8% early; 12.9% late[5]
Renal function preservationNo significant change in creatinine (p = 0.74)[5]
Median operative time360–402 min (open); 366–701 min (robotic)[5][21]
Median hospital stay6 days (open); 3 days (robotic)[5][21]
Pain resolution (LPHS)65–76%[5][10][11]

Complications​

The most common postoperative complications include:[4][5][6][15]

  • Hemorrhagic complications (9.7%) — the most common surgical complication.[4]
  • Graft vascular thrombosis (renal vein thrombosis more common than arterial) — the leading cause of early graft loss.[6][15]
  • Pseudoaneurysm formation — may present months to years postoperatively.[6][23]
  • Delayed graft function requiring temporary hemodialysis (16.6% in one series).[17]
  • Ureteral complications (stricture, leak).
  • Wound infection and blood transfusion (50% transfusion rate in complex oncologic cases).[17]

Predictors of morbidity include obesity (AOR 9.62), fluid/electrolyte disorders (AOR 3.67), preoperative CKD (AOR 1.80), and longer cold ischemia time (p = 0.049).[4][5]

Importantly, disease duration before autotransplantation does not influence outcomes, offering reassurance that the procedure can be performed at any point in the disease course without compromising results.[8]

Multidisciplinary Approach​

Optimal outcomes require collaboration among renal transplant surgeons, vascular surgeons, urologists, nephrologists, dieticians, pain management providers, social workers, and psychiatrists — particularly for LPHS patients where psychological comorbidity may affect outcomes.[1] The procedure should be performed at experienced, high-volume transplant centers.[3][4]

Key Takeaways​

RAT is a versatile, nephron-sparing salvage procedure that can prevent lifelong dialysis in patients who would otherwise be rendered anephric or face intractable disease. With >90% long-term graft survival in experienced hands, it remains an important tool in the upper-tract reconstructive armamentarium, though it requires careful patient selection, multidisciplinary planning, and vigilant long-term follow-up — particularly for oncologic indications, where local recurrence remains a concern.[1][6][15]

References​

1. Han DS, Johnson JP, Schulster ML, Shah O. "Indications for and Results of Renal Autotransplantation." Curr Opin Nephrol Hypertens. 2023;32(2):183–192. doi:10.1097/MNH.0000000000000860

2. Novick AC, Jackson CL, Straffon RA. "The Role of Renal Autotransplantation in Complex Urological Reconstruction." J Urol. 1990;143(3):452–457. doi:10.1016/s0022-5347(17)39988-3

3. Klein Nulend R, San Jose J, Canagasingham A, et al. "Kidney Autotransplantation: A Dual Centre Experience." ANZ J Surg. 2025. doi:10.1111/ans.70226

4. Moghadamyeghaneh Z, Hanna MH, Fazlalizadeh R, et al. "A Nationwide Analysis of Kidney Autotransplantation." Am Surg. 2017;83(2):162–169.

5. Cowan NG, Banerji JS, Johnston RB, et al. "Renal Autotransplantation: 27-Year Experience at 2 Institutions." J Urol. 2015;194(5):1357–1361. doi:10.1016/j.juro.2015.05.088

6. Tran G, Ramaswamy K, Chi T, et al. "Laparoscopic Nephrectomy With Autotransplantation: Safety, Efficacy and Long-Term Durability." J Urol. 2015;194(3):738–743. doi:10.1016/j.juro.2015.03.089

7. Machado M, Machado R, Almeida R. "Renal Autotransplantation for the Treatment of Renal Artery Aneurysm." Ann Vasc Surg. 2022;79:226–232. doi:10.1016/j.avsg.2021.07.048

8. Li KD, Pearce RJ, Sui W, et al. "Renal Autotransplantation: Association Between Preoperative Disease Duration and Surgical Outcomes." Urology. 2024;192:36–42. doi:10.1016/j.urology.2024.06.050

9. Spitz A, Huffman JL, Mendez R. "Autotransplantation as an Effective Therapy for the Loin Pain-Hematuria Syndrome: Case Reports and a Review of the Literature." J Urol. 1997;157(5):1554–1559.

10. Chin JL, Kloth D, Pautler SE, Mulligan M. "Renal Autotransplantation for the Loin Pain-Hematuria Syndrome: Long-Term Followup of 26 Cases." J Urol. 1998;160(4):1232–1235; discussion 1235–1236.

11. Sheil AG, Chui AK, Verran DJ, Boulas J, Ibels LS. "Evaluation of the Loin Pain/Hematuria Syndrome Treated by Renal Autotransplantation or Radical Renal Neurectomy." Am J Kidney Dis. 1998;32(2):215–220. doi:10.1053/ajkd.1998.v32.pm9708604

12. Xu Y, Huang J, Fan X, et al. "Clinical Experience of Bench Surgery Combined With Autotransplantation After Three-Dimensional Laparoscopic Nephrectomy for the Treatment of Highly Complex Renal Tumor." World J Surg Oncol. 2023;21(1):373. doi:10.1186/s12957-023-03246-9

13. Meng MV, Freise CE, Stoller ML. "Laparoscopic Nephrectomy, Ex Vivo Excision and Autotransplantation for Complex Renal Tumors." J Urol. 2004;172(2):461–464. doi:10.1097/01.ju.0000130668.94919.59

14. Zincke H, Sen SE. "Experience With Extracorporeal Surgery and Autotransplantation for Renal Cell and Transitional Cell Cancer of the Kidney." J Urol. 1988;140(1):25–27. doi:10.1016/s0022-5347(17)41475-3

15. Stormont TJ, Bilhartz DL, Zincke H. "Pitfalls of 'Bench Surgery' and Autotransplantation for Renal Cell Carcinoma." Mayo Clin Proc. 1992;67(7):621–628. doi:10.1016/s0025-6196(12)60715-0

16. Pettersson S, Brynger H, Henriksson C, et al. "Treatment of Urothelial Tumors of the Upper Urinary Tract by Nephroureterectomy, Renal Autotransplantation, and Pyelocystostomy." Cancer. 1984;54(3):379–386. doi:10.1002/1097-0142(19840801)54:3<379::AID-CNCR2820540304>3.0.CO;2-U

17. Janssen MWW, Linxweiler J, Philipps I, et al. "Kidney Autotransplantation After Nephrectomy and Work Bench Surgery as an Ultimate Approach to Nephron-Sparing Surgery." World J Surg Oncol. 2018;16(1):35. doi:10.1186/s12957-018-1338-1

18. Steffens J, Humke U, Alloussi S, Ziegler M, Siemer S. "Partial Nephrectomy and Autotransplantation With Pyelovesicostomy for Renal Urothelial Carcinoma in Solitary Kidneys: A Clinical Update." BJU Int. 2007;99(5):1020–1023. doi:10.1111/j.1464-410X.2007.06753.x

19. Holmäng S, Johansson SL. "Tumours of the Ureter and Renal Pelvis Treated With Resection and Renal Autotransplantation: A Study With Up to 20 Years of Follow-Up." BJU Int. 2005;95(9):1201–1205. doi:10.1111/j.1464-410X.2005.05505.x

20. McCabe M, Ellis E, Chacon A, et al. "Use of Cryopreserved Vascular Allograft Reconstruction in Robotic-Assisted Kidney Autotransplantation for Nutcracker Syndrome After Failed Renal Vein Transposition: Description of a Novel Technique." Surg Laparosc Endosc Percutan Tech. 2025. doi:10.1097/SLE.0000000000001400

21. Kaouk J, Chavali JS, Ferguson E, et al. "Single Port Robotic Kidney Autotransplantation: Initial Case Series and Description of Technique." Urology. 2023;176:87–93. doi:10.1016/j.urology.2023.02.030

22. Kaouk J, Eltemamy M, Aminsharifi A, et al. "Initial Experience With Single-Port Robotic-Assisted Kidney Transplantation and Autotransplantation." Eur Urol. 2021;80(3):366–373. doi:10.1016/j.eururo.2021.03.002

23. Eisenberg ML, Lee KL, Zumrutbas AE, et al. "Long-Term Outcomes and Late Complications of Laparoscopic Nephrectomy With Renal Autotransplantation." J Urol. 2008;179(1):240–243. doi:10.1016/j.juro.2007.08.135